(3R,4R)-4-Amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
| Title | Journal |
|---|---|
| A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. | Cancer chemotherapy and pharmacology 20121001 |
| In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
| Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine. | Chemical research in toxicology 20110114 |
| Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. | Drug metabolism and disposition: the biological fate of chemicals 20101101 |
| Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. | Journal of pharmaceutical sciences 20100801 |
| BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. | British journal of cancer 20100727 |
| Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs. | Drug metabolism and disposition: the biological fate of chemicals 20100701 |
| A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. | Cancer research 20070701 |